{
  "file_name": "HOUSE_OVERSIGHT_013482.txt",
  "file_path": "001\\HOUSE_OVERSIGHT_013482.txt",
  "content": {
    "full_text": "From: Steven Victor MD 111.11111..... \nSent: 11/23/2012 1:06:38 PM \nTo: \nCC: \nSubject: Report on Stem Cells future \nPUBLISHED: 22 NOVEMBER 2012 \nThe view from the US: Stem cell therapy steps up a gear with first \napproval and improved political climate \nSpecial Report \nPeter Winter \nPositive clinical data, increases in federal funding and the first regulatory approval of a manufactured stem \ncell product mean momentum is building in the US. With the re-election of President Obama, this is likely to \nconf nue \nShare on twitterShare on linkedinShare on facebookShare on email  \nImage: Bigstock \nWhen US President Barack Obama came into office he made good on his promise to overturn President George W. Bush's executive \norder that - with the exception of a handful of existing stem cell lines - prohibited federal funding of human embryonic stem cell (hESC) \nresearch. \nSpecial Report - Stem Cell Research under Horizon 2020 \nStem Cell Research in Horizon 2020: Experts debate what Europe must do to maintain its lead in regenerative medicine  \nThe view from the US: Stem cell therapy steps up a gear with first approval and improved political climate  \nView from Europe: Delivering on the vision of regenerative medicine and stem cells  \nTalking to the experts: Why the EU should support human embryonic stem cell research in Horizon 2020  \nOVERVIEW: Regenerate the future - human embryonic stem cell research is crucial to deliver health and growth  \nThis easing of restrictions on hESC research was expected to engender enough confidence to attract investors into the space and \nencourage pharmaceutical and biotech companies to build robust product pipelines based on stem cell therapies. However, a tougher \nregulatory climate for biopharmaceuticals in general and a protracted legal challenge to the relaxing of rules on hESCs has served to \nkeep both big pharma companies and venture capitalists on the sidelines to date. \nNevertheless, there has been progress, particularly at the research end of the development spectrum. Three and a half years on stem \ncells are no longer high on the political agenda as they once were. This speaks to the generally positive public acceptance of stem cell \nresearch in the US. A Research!America poll of likely voters in the presidential election, conducted in August 2012, found that 61 per \ncent of prospective voters were in favor of expanding funding for hESC research. \nInvestor interest \nLooking back over his first term in office Obama can point to some major gains. These include funding increases for the National \nInstitutes of Health's (NIH) stem cell initiatives, and greater investor interest in the wider field of regenerative medicine including the use \nof adult stem cells and induced pluripotent stem (iPS) cells. \nHowever, it hasn't all been smooth sailing. Although after protracted forethought, the US Food and Drug Administration (FDA) gave the \ngreen light for the Californian biotech Geron to begin the very first human clinical trial of a human embryonic stem cell-derived therapy \nin January 2009, the trial has not been without its problems. \nThe Phase I trial, treating patients with acute spinal cord injury, was hit with an FDA clinical hold causing significant delays to its \ninitiation in 2010. A year later, after 15 years' effort, the Geron washed its hands of the programme, blaming its withdrawal from the \nstem cell space on capital scarcity and uncertain economic conditions. The decision wiped out a leading player in hESC translation and \ncommercialisation. However, the regenerative medicine sector has been able to recover and is beginning to blossom. (See Public \nMarkets section below). The prime movers in the Geron trial are now attempting to revive it. \nResearch funding robust \nFederal funding for all forms of stem cell research has increased over the past four years. However, the NIH funding component for \nhESC has been dogged by litigation for the past three years. In Sherley v. Sebelius, researchers James Sherley and Theresa Deisher, \nwho worked with adult stem cells, claimed the NIH guidelines violated the Dickey-Wicker Amendment, which prohibits the use of federal \nfunds for research in which human embryos are destroyed or discarded. This overhang was not finally removed until August 2012 when \na three-judge panel from the US Court of Appeals for the District of Columbia Circuit unanimously upheld the NIH 2009 guidelines that \npermit funding of hESC research. \nHOUSE OVERSIGHT 013482 \nThrough its Common Fund the NIH has established the Center for Regenerative Medicine (NIH CRM), to support this field, with the \ngoal of accelerating the translation of stem cell-based clinical therapies. \nState funding filling the void \nWith stem cell research in general not attracting a significant amount of venture funding, the California Institute of Regenerative \nMedicine (CIRM), which was established in 2004 with $3 billion for stem cell research at California universities and research institutions, \nhas begun to fill the void left by traditional venture capital firms. To date CIRM has allocated $150 million in funding to help move \npromising stem cell-based therapies from the bench into clinical trials. \n'We are a lot closer to having promising therapies ready for clinical trials, so it makes sense that we step up our engagement with \nindustry to help fund those trials and move those therapies closer to approval by the FDA,\" said Duane Roth, vice chair of the governing \nboard of CIRM. \nCIRM's funding for translational research is good news for biotech companies, providing them with a source of funds in a field where it \nremains challenging to raise private capital. \nThree biotech companies have been funded so far under CIRM's Strategic Partnership Awards initiative. A grant of $10.1 million was \nawarded to ViaCyte Inc. to continue preclinical research and initiate clinical testing of an embryonic stem cell-based therapy for patients \nwith insulin-dependent diabetes. \nMeanwhile, Bluebird Bio Inc. will use a $9.3 million grant to support a Phase I/II study to evaluate the safety and efficacy of LentiGlobin, \nthe company's programme for the treatment of the inherited blood disorder beta-thalassemia, which will be initiated in the US in 2013. \nStemCells Inc. has been awarded up to $20 million to fund preclinical development of its product consisting of purified human neural \nstem cells for treating Alzheimer's disease, with the goal of filing for permission to carry out a clinical trial in that time. In July, CIRM \napproved a separate award to the company for up to $20 million to fund preclinical development of a cell therapy for spinal cord injury. \nPublic Markets \nIt has been a good year for stem cell companies on the public markets, with the thirteen publicly-listed stem cell companies showing an \naverage increase in share price of 11.6 percent in the year-to-date. \nThis boost came from a regulatory approval and positive clinical trials results. It was a big breakthrough for the field as a whole when \nthe Canadian regulator Health Canada approved Prochymal, Osiris Therapeutics Inc.'s allogeneic stem cell treatment for graft-vs.-host \ndisease (GvHD) in children. \nThe decision marked the world's first regulatory approval of a manufactured stem cell product and the first therapy approved for GvHD \nâ€” a devastating complication of bone marrow transplantation that kills up to 80 percent of children affected, many within just weeks of \ndiagnosis. The company's stock value has almost doubled in the course of this year. \nMeanwhile, Newark, California-based StemCells, Inc. has seen its shares rise 148 per cent in the year to date. In addition to its CIRM \ngrants, the company recently reported clinical and preclinical data demonstrating the therapeutic potential of a cell therapy for treating \nmyelination disorders. \nPluristem Therapeutics Inc.'s stock value also has jumped 44 per cent, on the strength of reporting a single case study in wh ich a \npatient with aplastic bone marrow who received an intramuscular injection of its PLacental eXpanded cells under compassionate use \nsaw an improvement. The company was also able to successfully complete a public offering which netted about US$30 million. \nPositive clinical trials will begin to encourage investment \nWhile still in their early stages of development - and with clinical trials having only involved a limited number of patients - reports to date \nhave been very promising, and provide further validation for encouraging investment in stem cell therapeutics. For example, data from a \nhuman embryonic stem cell trial conducted by Advanced Cell Technology and published in medical journal The Lancet, showed that \ntwo patients with Stargardt's disease, a degenerative eye condition, had regained some vision. \nIn addition, positive early data from a spinal cord injury trial involving StemCells' neural stem cells indicated that two patients with no \nfeeling below the site of injury were able to regain sensation, while in another study from the company, patients with a rare myelination \ndisorder were able to create myelin, an advance that holds promise for treating multiple sclerosis and cerebral palsy. \nThis scientific progress has helped breath a new sense of optimism into the US stem cell sector. The Fiscal Cliff apart, it seems likely \nthis momentum will continue now Obama has secured a second term. \nPeter Winter is a writer, editor and analyst on the global biotechnology industry. He is currently editor of BioWorld Insight. \nSteven Victor MD \nIntelliCell BioSciences \nChairman/CEO \n460 Park Avenue 17th Floor \nNew York, New York 10022 \nwww.IntelliCellBioSciences.com \nHOUSE OVERSIGHT 013483 \n"
  },
  "error": "LLM request failed: 429 RESOURCE_EXHAUSTED. {'error': {'code': 429, 'message': 'You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/usage?tab=rate-limit. \\n* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 20, model: gemini-3-flash\\nPlease retry in 46.631504909s.', 'status': 'RESOURCE_EXHAUSTED', 'details': [{'@type': 'type.googleapis.com/google.rpc.Help', 'links': [{'description': 'Learn more about Gemini API quotas', 'url': 'https://ai.google.dev/gemini-api/docs/rate-limits'}]}, {'@type': 'type.googleapis.com/google.rpc.QuotaFailure', 'violations': [{'quotaMetric': 'generativelanguage.googleapis.com/generate_content_free_tier_requests', 'quotaId': 'GenerateRequestsPerDayPerProjectPerModel-FreeTier', 'quotaDimensions': {'location': 'global', 'model': 'gemini-3-flash'}, 'quotaValue': '20'}]}, {'@type': 'type.googleapis.com/google.rpc.RetryInfo', 'retryDelay': '46s'}]}}",
  "house_oversight_id": "013482",
  "processing_metadata": {
    "processed_at": "2025-12-20T00:22:13.486987Z",
    "model": "gemini-3-flash-preview"
  }
}